| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2023 | 1350 | 1.430 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 972 | 1.330 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 967 | 1.330 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 385 | 1.240 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 425 | 1.110 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 130 | 0.920 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 565 | 0.880 |
Why?
|
| Lymph Nodes | 5 | 2019 | 374 | 0.810 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.720 |
Why?
|
| Gender Identity | 1 | 2021 | 73 | 0.680 |
Why?
|
| Veterans | 7 | 2024 | 1744 | 0.670 |
Why?
|
| Patient Transfer | 1 | 2021 | 107 | 0.660 |
Why?
|
| Natural Language Processing | 2 | 2024 | 73 | 0.650 |
Why?
|
| Transgender Persons | 1 | 2021 | 66 | 0.650 |
Why?
|
| Cancer Survivors | 2 | 2021 | 258 | 0.640 |
Why?
|
| Fatigue | 1 | 2021 | 196 | 0.630 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 429 | 0.610 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 384 | 0.600 |
Why?
|
| Exercise Therapy | 1 | 2021 | 171 | 0.600 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 223 | 0.600 |
Why?
|
| Gastrectomy | 2 | 2021 | 98 | 0.590 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 1291 | 0.530 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 696 | 0.530 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1759 | 0.530 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 76 | 0.510 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 61 | 0.470 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 114 | 0.470 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 94 | 0.460 |
Why?
|
| Electronic Health Records | 3 | 2024 | 781 | 0.410 |
Why?
|
| Aged | 25 | 2024 | 20525 | 0.400 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1395 | 0.400 |
Why?
|
| Databases, Factual | 2 | 2018 | 1199 | 0.360 |
Why?
|
| Hospitals | 3 | 2020 | 428 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1311 | 0.350 |
Why?
|
| HIV Infections | 1 | 2023 | 1954 | 0.340 |
Why?
|
| Middle Aged | 20 | 2024 | 27900 | 0.320 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6719 | 0.310 |
Why?
|
| Retrospective Studies | 15 | 2023 | 17111 | 0.310 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 152 | 0.310 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1370 | 0.310 |
Why?
|
| Physician's Role | 1 | 2011 | 164 | 0.300 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 86 | 0.300 |
Why?
|
| Algorithms | 1 | 2016 | 1639 | 0.300 |
Why?
|
| Communication | 2 | 2022 | 513 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1055 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 154 | 0.270 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1238 | 0.270 |
Why?
|
| Humans | 35 | 2024 | 127627 | 0.260 |
Why?
|
| Male | 25 | 2024 | 62967 | 0.260 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 118 | 0.260 |
Why?
|
| Female | 23 | 2024 | 68835 | 0.230 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 623 | 0.220 |
Why?
|
| Primary Health Care | 1 | 2011 | 781 | 0.220 |
Why?
|
| Neoplasms | 4 | 2024 | 2852 | 0.210 |
Why?
|
| United States | 11 | 2021 | 11427 | 0.210 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 875 | 0.190 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 77 | 0.190 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 257 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2016 | 393 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 743 | 0.180 |
Why?
|
| Frailty | 1 | 2024 | 131 | 0.180 |
Why?
|
| Adult | 10 | 2021 | 30628 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 900 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2019 | 12601 | 0.160 |
Why?
|
| Emotions | 2 | 2021 | 356 | 0.160 |
Why?
|
| Palliative Care | 2 | 2018 | 437 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 87 | 0.150 |
Why?
|
| Comorbidity | 3 | 2019 | 1564 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1110 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 261 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 28 | 0.140 |
Why?
|
| Young Adult | 4 | 2021 | 9704 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 23 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 26 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 100 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 15 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 104 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 68 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2017 | 64 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 267 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 355 | 0.130 |
Why?
|
| Veterans Health | 1 | 2018 | 171 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2017 | 144 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 133 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2021 | 4991 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 490 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 124 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 125 | 0.120 |
Why?
|
| Motor Activity | 1 | 2019 | 504 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 882 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1218 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 124 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 227 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 316 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 309 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 758 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 694 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 259 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 1540 | 0.110 |
Why?
|
| Adolescent | 4 | 2021 | 20176 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2017 | 1500 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2240 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 221 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 370 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 510 | 0.090 |
Why?
|
| Hospitalization | 1 | 2021 | 1878 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 742 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1240 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 561 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 254 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 714 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 179 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2032 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 989 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2082 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2011 | 61 | 0.080 |
Why?
|
| Piperidines | 1 | 2012 | 224 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 99 | 0.080 |
Why?
|
| Survival Rate | 3 | 2021 | 2111 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 228 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 229 | 0.080 |
Why?
|
| Gait | 2 | 2021 | 145 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 341 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1494 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 540 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 4804 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 26 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 37 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 660 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 554 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 248 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 201 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1775 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 3938 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1562 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2012 | 4492 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 553 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1388 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2021 | 116 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2339 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2587 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1409 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 2816 | 0.030 |
Why?
|
| Exercise | 1 | 2024 | 845 | 0.030 |
Why?
|
| Attention | 1 | 2019 | 195 | 0.030 |
Why?
|
| Postural Balance | 1 | 2019 | 130 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2019 | 207 | 0.030 |
Why?
|
| Diplopia | 1 | 2017 | 43 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 269 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 132 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 167 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 359 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 156 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 24 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 68 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 134 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 962 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 637 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 59 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1141 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3255 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 64 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 149 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 345 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3336 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 684 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 181 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 287 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3001 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 429 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 332 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 687 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 317 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 382 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1791 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 3 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 14 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1008 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 715 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 21 | 0.020 |
Why?
|
| New York | 1 | 2008 | 69 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3598 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 576 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 47 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 2626 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2126 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 169 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1382 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5170 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 219 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 630 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 404 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 873 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1178 | 0.010 |
Why?
|
| Family | 1 | 2008 | 580 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1932 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10645 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6266 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 33234 | 0.010 |
Why?
|